Showing 881-890 of 4902 results for "".
- Modernizing Medicine Completes $12 Million Capital Raisehttps://practicaldermatology.com/news/20130111-modernizing_medicine_completes_12_million_capital_raise/2459639/Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, completed a $12 million capital raise, with a combination of equity capital and a senior bank debt facility. The company plans to use the funding to, among other things, acc
- AMA Releases National EHR Survey for Physician Inputhttps://practicaldermatology.com/news/20121012-ama_releases_national_ehr_survey_for_physician_input/2459708/The American Medical Association (AMA) electronically invited member physicians to share their insights and opinions on the latest electronic health record (EHR) technology through a joint survey with AmericanEHR Partners. Findings are intended to support physicians in the selection, use, and value
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- Physicians Report Health IT Growing But Systems Laghttps://practicaldermatology.com/news/20120921-physicians_report_health_it_growing_but_systems_lag/2459732/A new Optum Institute/Harris Interactive national survey provides insights into US consumers' willingness to view their medical records and engage with care providers online. The survey was conducted online within the United States among 1,000 US physicians, 2,870 US adults, and 400 US hospital exec
- Syneron Receives FDA Clearance for elōs Plushttps://practicaldermatology.com/news/20120712-syneron_receives_fda_clearance_for_els_plus/2459774/Syneron Medical Ltd. (NASDAQ: ELOS) received US Food and Drug Administration (FDA) clearance for elōs Plus, a multi-platform system featuring the company's proprietary elōs technology of optical energy and bi-polar radiofrequency. The FDA clearance follo
- DocBookMD App Offers Secure Communication, HIPAA Compliancehttps://practicaldermatology.com/news/20120424-docbookmd_app_offers_secure_communication_hipaa_compliance/2459816/Doctors can now send X-rays and lab results back and forth, securely and with full HIPAA compliance via a new application, available for iPhone, iPad, and Android. The DocBookMD app is free for doctors who are members of their state or county medical society. All activity is run through a secure ser
- National Academy of Dermatology Nurse Practitioners Inaugural Conference in Mayhttps://practicaldermatology.com/news/20120224-national_academy_of_dermatology_nurse_practitioners__inaugural_conference_in_may/2459865/The inaugural conference of the National Academy of Dermatology Nurse Practitioners will be held May 2-5, 2012 in Clearwater Beach, FL at the Sheraton Sand Key Resort. Designed for all nurse practitioners regardless of experience or practice seting, the program covers both medical and aesthetic derm
- Science of Skin Summit: AI in Medicine Requires More Than Knowing Which Model Scores Besthttps://practicaldermatology.com/news/science-of-skin-summit-ai-in-medicine-requires-more-than-knowing-which-model-scores-best/2488531/Artificial intelligence models are evolving so rapidly that clinicians may struggle to determine which tools they can trust, but choosing the model that performs best on a standardized test may not provide the answer. Speaking at the Science of Skin Summit, Roxana Daneshjou, MD, PhD, discu
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20